Arrhythmogenic cardiomyopathy is a major cause of sudden death among young people. Three studies show that gene therapy to restore the desmosomal protein PKP2 holds promise in improving the prognosis of affected individuals.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pérez-Hernández, M. et al. Front Physiol. 11, 623190 (2021).
Oxford, E. M. et al. Circ. Res. 101, 703–711 (2007).
Sato, P. Y. et al. Circ. Res. 105, 523 (2009).
Bradford, W. H. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-023-00370-3 (2023).
Kyriakopoulou, E. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-023-00378-9 (2023).
Wu, I. et al. Commun. Med. (in the press).
Gerull, B. et al. Nat. Genet. 36, 1162–1164 (2004).
Cerrone, M. et al. Cardiovasc Res. 95, 460–468 (2012).
Denegri, M. et al. Circulation. 129, 2673–2681 (2014).
Lek, A. et al. N. Engl J. Med. 389, 1203–1210 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests
Rights and permissions
About this article
Cite this article
Priori, S.G. Restoring PKP2 in arrhythmogenic cardiomyopathy. Nat Cardiovasc Res 2, 1115–1116 (2023). https://doi.org/10.1038/s44161-023-00382-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s44161-023-00382-z